Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug called carfilzomib used in combination with another
drug called belinostat with participants who have relapsed or refractory non-Hodgkin lymphoma
(NHL).